Guilrerey et al. [77] verified that the percentage of CD8 + TIGIT + cells was strongly correlated with myeloma load by in vivo experiments in Vκ*MYC mice, and found that TIGIT was expressed more frequently than other checkpoints by examining CD8 + T cells from human patients, and therefore hypothesized that treatment of wild-type myeloma recipients with an anti-TIGIT antibody could reduce tumor load. The gene discussed is CD8A; the disease is plasma cell myeloma.